Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Author:

Flynn Michael J.¹,Sayed Anwar A.²³,Sharma Rohini⁴,Siddique Abdul⁴,Pinato David J.⁴

Affiliation:

1. Department of Medicine The Royal Marsden NHS Foundation Trust London United Kingdom

2. Centre for Haematology Imperial College London London United Kingdom

3. Department of Medical Microbiology and Immunology Taibah University Medina Saudi Arabia

4. Department of Surgery & Cancer Imperial College London, Hammersmith Hospital London United Kingdom

Publisher

Wiley

Subject

Hepatology

Link

Reference71 articles.

1. Dr William Coley and tumour regression: a place in history or in the future;Hoption Cann SA;Postgrad Med J,2003

2. Comparison of the accuracy of AASLD and LI‐RADS criteria for the non‐invasive diagnosis of HCC smaller than 3 cm;Ronot M;J Hepatol,2017

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献